Munguva ichangopfuura, Shanghai Epiprobe Biotechnology Co., Ltd. (inoti "Epiprobe") yakazivisa kuti yakanga yapedza inoda kusvika RMB 100 miriyoni muSeries B mari, iyo inoiswa pamwe chete nemari yemaindasitiri, mapuratifomu ekudyara ehurumende uye kambani yakanyorwa Yiyi Shares (SZ). :001206).
Yakavambwa muna 2018, Epiprobe, semutsigiri uye piyona wepakutanga pan-cancer kuongororwa, ibhizimusi repamusoro-soro rinotarisa pagomarara rekuongorora chirwere uye indasitiri yemishonga chaiyo.Kuvaka pachikwata chepamusoro che epigenetics nyanzvi uye kuunganidza kwakadzika kwedzidzo, Epiprobe inotsvaga ndima yekuonekwa kwegomarara, inotsigira chiono che "kuchengetedza munhu wese kure negomarara," akazvipira kuongororwa nekukurumidza, kuongororwa kwekutanga uye kurapwa kwegomarara, nekudaro kuvandudza kupona. mwero wevarwere vegomarara kusimudzira hutano hwevanhu vese.
Mushure mekuchera kwemakore makumi maviri, Epiprobe's core timu yakazvimiririra yakawana nhevedzano yegomarara Aligned General Methylated Epiprobes (TAGMe), ayo ari pasi rose mumakenza akasiyana siyana, nokudaro achiwedzera zvakanyanya ndima yekushandisa.
Nezve tekinoroji yekuona, pyrosequencing inogara ichionekwa se "goridhe mwero" yekuona methylation, iyo zvakadaro inotsamira pakushandurwa kwebisulfite, asi inoratidzira zvikanganiso senge kusarongeka kwekushandura, kushatisa kuri nyore kweDNA, zvinodiwa zvakanyanya kune vanoshanda, uye kuvimba nezviridzwa zvakakosha.Kushaikwa uku kunoganhurira kushandiswa kwayo.Epiprobe, kuburikidza nekugadzira mabhindauko ehunyanzvi, yakazvimiririra yakagadzira tekinoroji yekuongorora methylation - Me-qPCR isina kurapwa kwebisulfite, iyo inoderedza mutengo uye inovandudza kugadzikana kwekuona uye kushanda kwekiriniki, zvichiita kuti kuona kuve nyore uye nyore.
Epiprobe, yakanangana neiyo core pan-cancer marker yekambani uye nzira dzekuongorora methylation, yakashandisa pamatendi makumi mashanu epamba neekunze kwenyika, uye yakawana mvumo yekumisikidza yakasimba patent.
Parizvino, Epiprobe yakashanda pamwe nepamusoro pezvipatara makumi mana zvepamusoro muChina, zvinosanganisira Zhongshan Hospital, International Peace Maternity uye Child Health Hospital, uye Changhai Hospital nezvimwe, uye yakashandisa hurongwa hwakakura hwechigadzirwa mumakenza ekubereka echikadzi (kusanganisira gomarara rechibereko, endometrial cancer) , kenza yeurothelial (kusanganisira kenza yedundira, kenza yeurterral, renal pelvis cancer), kenza yemapapu, kenza yethyroid, kenza yeropa uye mamwe magomarara.Iyo yakapetwa kaviri-mapofu yekusimbisa yakaitwa mu70,000 ekiriniki samples aine makumi maviri neshanu marudzi egomarara.
Pakati pezvigadzirwa, zvezvigadzirwa zvekuona kenza yegomarara revakadzi, kusimbiswa kwakapetwa kaviri kwakaitwa mumakiriniki anopfuura zviuru makumi mana, uye nhevedzano yetsvakiridzo yakaburitswa mumapepanhau ane mukurumbira pasi rose seCancer Research, Clinical and Translational Medicine, uye. makiriniki akawanda makuru-epakati akawanda ari kuitwa.Sezvo R&D ichifambira mberi uye zviwanikwa zvichiramba zvichiwedzera, pombi yezvigadzirwa zvekambani iri kuramba ichiwedzera.
Mai Hua Lin, CEO weEpiprobe vakati: “Kukudzwa kwedu kukuru kuzivikanwa nekutsigirwa nemaguta makuru eindasitiri.Epiprobe inoratidzwa nekuunganidza kwayo kwakadzama kwedzidzo, tekinoroji yakasarudzika, uye tsvakiridzo yekiriniki yakasimba, iyo yakakunda kuvimba nemapato mazhinji.Kwemakore mana apfuura, timu yekambani uye mashandiro akawedzera kuwedzera.Mumazuva anouya, hatizoregi kukoka vamwe vane pfungwa dzakafanana kuti vashande pamwe nekushanda pamwe chete, nekudaro tichigara tichisimudzira R&D uye chirongwa chekunyoresa kunyorera, pamwe nekupa varapi nevarwere mabasa epamusoro ekuongorora cancer uye zvigadzirwa."
Nguva yekutumira: Kubvumbi-11-2022